Connect with us

Hi, what are you looking for?

Financial Source ReportFinancial Source Report

Tech News

23andMe is ending its cancer research program and slashing over 200 jobs

An image showing the 23andMe sign
Photo by Justin Sullivan/Getty Images

23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s massive data breach and reverse its plummeting stock price. The genetic testing company also announced that it will shut down its therapeutics business.

Though 23andMe says the restructuring plan will cost it around $12 million, it expects to save more than $35 million as a result, while “substantially” lowering operating expenses. 23andMe’s therapeutics division, which studied potential cancer treatments using its database of genetic material, will end all clinical trials, as the company considers licensing agreements or asset sales to “maximize” the program’s value.

23andMe has had a turbulent past year, with the…

Continue reading…

You May Also Like

Editor's Pick

The “Magnificent 7”, comprised of Apple (AAPL), Microsoft (MSFT), NVIDIA (NVDA), Meta Platforms (META), Amazon.com (AMZN), Alphabet (GOOGL), and Tesla (TSLA) have carried the...

Tech News

Three advocacy groups are trying to amp up the pressure on Google for allegedly destroying company records. The American Economic Liberties Project, Check My...

Editor's Pick

Romina Boccia Ida May Fuller, the first person to receive a Social Security check, worked for just three years before receiving her first benefit...

Tech News

It’s time to dust off your VCR and clean the heads, because Alien: Romulus is coming to VHS as a limited edition on December...

Copyright © 2023 FinancialSourceReport.com All Rights Reserved.